Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04273594 · ClinicalTrials.gov registry record · NA

FemBloc® Permanent Contraception - Confirmation Feasibility Trial

A NA study of Contraception, sponsored by Femasys.

Active
Registry status
NA
Development phase
45
Enrollment target
6
Study locations

NCT04273594 is a NA study of Contraception that is active but no longer recruiting, run by Femasys. The registered enrollment target is 45 participants, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (90% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04273594, a NA study of Contraception, is active but no longer recruiting, sponsored by Femasys.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
45 participants
Enrollment target
6
Study locations

Study Summary

The trial objectives include evaluating the adequacy of proposed mitigations for the previous pivotal trial of the FemBloc Permanent Contraceptive System and validating the confirmation procedure by comparing FemChec (ultrasound) to fluoroscopic hysterosalpingogram (fluoro HSG) for post-occlusion in the same patient.

Conditions Studied

Interventions

  • DEVICE FemBloc

Study Locations (6)

Arizona

  • New Horizons Clinical Trials - Chandler
  • Precision Trials AZ, LLC - Phoenix

Georgia

  • Midtown OB GYN North - Columbus

Indiana

  • Women's Health Advantage - Fort Wayne

Michigan

  • Saginaw Valley Medical Research Group - Saginaw

Ohio

  • University Hospitals - Cleveland Medical Center - Beachwood

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2020-02-27
Est. Completion 2027-04
Phase NA

Sponsor

Femasys

5 total trials

What the Registry Record Tells You About NCT04273594

The ClinicalTrials.gov registry entry for NCT04273594 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (90% lower). The listed sponsor is Femasys, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 1 intervention - of which FemBloc is the first listed.

NCT04273594 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Arizona, Georgia, Indiana.

Frequently Asked Questions

What is clinical trial NCT04273594 about?

NCT04273594 is a clinical study titled "FemBloc® Permanent Contraception - Confirmation Feasibility Trial". The trial objectives include evaluating the adequacy of proposed mitigations for the previous pivotal trial of the FemBloc Permanent Contraceptive System and validating the confirmation procedure by comparing FemChec (ultrasound) to fluoroscopic hysterosalpingogram (fluoro HSG) for post-occlusion in...

What is the current status of trial NCT04273594?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2020-02-27. Estimated completion is 2027-04.

What conditions does trial NCT04273594 study?

This clinical trial studies the following conditions: Contraception.

What interventions are being tested in trial NCT04273594?

The interventions under investigation include: FemBloc (DEVICE).

Who is sponsoring clinical trial NCT04273594?

This trial is sponsored by Femasys, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04273594 being conducted?

This trial has 6 study locations across Arizona, Georgia, Indiana, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Contraception

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.